UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 626.2	$ 1,068.2
Short-term investments	0.0	100.0
Accounts receivable, net	421.3	416.9
Inventories	749.5	710.1
Assets held for sale	0.0	4.4
Other current assets	239.6	172.2
Total current assets	2,036.6	2,471.8
Property, plant and equipment, net	421.5	406.1
Goodwill	381.5	339.5
Intangible assets, net	214.0	211.8
Other long-term assets	283.3	220.8
Total assets	3,336.9	3,650.0
Current liabilities:
Current portion of long-term debt	17.0	112.4
Accounts payable	157.7	147.4
Customer advances	175.5	197.5
Other current liabilities	514.4	481.2
Total current liabilities	864.6	938.5
Long-term debt	1,136.8	1,221.8
Other long-term liabilities	381.8	404.9
Commitments and contingencies (Note 14)
Redeemable noncontrolling interests	5.7	0.2
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding	0.0	0.0
Common stock, $0.01 par value 260,000,000 shares authorized, 175,297,676 and 174,905,035 shares issued and 147,366,634 and 150,753,687 shares outstanding at September 30, 2022 and December 31, 2021, respectively	1.7	1.7
Treasury stock, at cost, 27,931,042 and 24,151,348 shares at September 30, 2022 and December 31, 2021, respectively	(1,058.6)	(820.3)
Accumulated other comprehensive loss, net of tax	(92.1)	(8.2)
Other shareholders' equity	2,086.0	1,897.3
Total shareholders' equity attributable to Bruker Corporation	937.0	1,070.5
Noncontrolling interests in consolidated subsidiaries	11.0	14.1
Total shareholders' equity	948.0	1,084.6
Total liabilities, redeemable noncontrolling interests and shareholders' equity	$ 3,336.9	$ 3,650.0